Document is current
Any future updates will be listed below
-
Authors
Behzadi, Arvin https://orcid.org/0000-0002-9347-0364
Pujol-Calderón, Fani https://orcid.org/0000-0001-7920-2884
Tjust, Anton E. https://orcid.org/0000-0003-2369-4319
Wuolikainen, Anna https://orcid.org/0000-0003-0838-5526
Höglund, Kina https://orcid.org/0000-0002-1213-9953
Forsberg, Karin https://orcid.org/0000-0003-2911-6026
Portelius, Erik https://orcid.org/0000-0003-2708-7372
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Andersen, Peter Munch https://orcid.org/0000-0003-0094-5429
-
Funding
Funding for this research was provided by:
Region Västernorrland (LVNFOU939000)
Horizon 2020 (633413, 860197)
Hjärnfonden (2012-0262, 2012-0305, 2013-0279, 2016-0303, 2020-0353)
the Ulla-Carin Lindquist Foundation
Alzheimer's Drug Discovery Foundation (RDAPB-201809-2016615)
EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
Swedish Alzheimer Foundation (AF-742881)
Knut och Alice Wallenbergs Stiftelse (2012.0091, 2014.0305, 2020.0232)
Vetenskapsrådet (2012-0262, 2012-0305, 2013-0279, 2016-0303, 2020-0353)
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Umea University
- License Information
-
More Information
Article History
Received: 21 May 2021
Accepted: 27 October 2021
First Online: 11 November 2021
Competing interests
: A.B. declares no disclosures relevant to the manuscript. F.P.C. declares no disclosures relevant to the manuscript. A.E.T. declares no disclosures relevant to the manuscript. A.W. declares no disclosures relevant to the manuscript. K.H. declares no disclosures relevant to the manuscript. K.F. declares no disclosures relevant to the manuscript. E.P. declares no disclosures relevant to the manuscript. K.B. served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. H.Z. reports that he has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. P.M.A. reports grants from the Swedish Research Council, the Swedish Brain Foundation, the Knut and Alice Wallenberg Foundation, the Ulla-Carin Lindquist Foundation; has been/is a consultant for Biogen, Orphazyme A/S, Hoffman la Roche/Genentech and Regeneron on matters regarding ALS genetics and clinical trials.
